Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $21.64, but opened at $20.39. Genmab A/S shares last traded at $20.23, with a volume of 657,605 shares traded.

Wall Street Analysts Forecast Growth

GMAB has been the topic of a number of analyst reports. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. BMO Capital Markets reissued an "outperform" rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, January 8th. Finally, Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Trading Down 2.0 %

The business has a fifty day simple moving average of $21.19 and a two-hundred day simple moving average of $24.10. The company has a market cap of $13.77 billion, a PE ratio of 20.20, a price-to-earnings-growth ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million during the quarter, compared to analysts' expectations of $838.20 million. During the same period in the prior year, the business posted $0.47 earnings per share. Equities analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Institutional Trading of Genmab A/S

Several large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in shares of Genmab A/S by 4.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company's stock valued at $1,763,000 after acquiring an additional 3,283 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company's stock valued at $470,000 after buying an additional 1,236 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after buying an additional 103,859 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after buying an additional 478 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after acquiring an additional 145,689 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.